Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence (Q37762149)

22 August 2017

1 reference

title

Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence (English)

1 reference

22 August 2017

Kumaran Kolandaivelu

1

1 reference

22 August 2017

Deepak L Bhatt

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Nature Reviews Cardiology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

461-467

1 reference

Scientific and therapeutic advances in antiplatelet therapy

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Intensifying platelet inhibition--navigating between Scylla and Charybdis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Assessment of bleeding events in clinical trials--proposal of a new classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Prasugrel versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Antiplatelet 'resistance' and 'non-responders': what do these terms really mean?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Aspirin and clopidogrel resistance: an emerging clinical entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Aspirin resistance: more than just a laboratory curiosity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cytochrome p-450 polymorphisms and response to clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Genetic determinants of response to clopidogrel and cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Proton pump inhibitors and clopidogrel: putting the interaction in perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Platelet function monitoring in patients with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Resisting the temptation to oversimplify antiplatelet resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Intravenous platelet blockade with cangrelor during PCI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Platelet inhibition with cangrelor in patients undergoing PCI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Impact of medication therapy discontinuation on mortality after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

31 March 2020

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.71

Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20517286

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2010.71

1 reference

22 August 2017

1 reference